Carregant...
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
Diabetic patients suffer from a high rate of cardiovascular events and such risk increases with HbA1c. However, lowering HbA1c does not appear to yield the same benefit on macrovascular endpoints, as observed for microvascular endpoints. As the number of glucose-lowering medications increases, clini...
Guardat en:
Publicat a: | Cardiovasc Diabetol |
---|---|
Autors principals: | , , , , |
Format: | Artigo |
Idioma: | Inglês |
Publicat: |
BioMed Central
2016
|
Matèries: | |
Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4982334/ https://ncbi.nlm.nih.gov/pubmed/27514514 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-016-0431-4 |
Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|